21ST CENTURY HEADLINES: Bristol Myers buys Nvidia’s latest AI computing system for drug research.

The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD ​based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.

Financial terms of the Bristol Myers investment were not disclosed. It builds on a smaller SuperPOD system the drugmaker ‌bought from Nvidia, which is ⁠around two or three generations behind Vera Rubin, BMS executives said in an interview.

Pharmaceutical companies are increasingly investing in AI infrastructure to try ⁠to identify drug targets faster and improve the odds that experimental drugs succeed in clinical trials.

We sure could use some new antibiotics in a hurry.